A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON)

Trial Profile

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms BEACON
  • Sponsors Allergan
  • Most Recent Events

    • 10 Oct 2016 According to Allergan media release, new data will be presented at the 2016 American Academy of Ophthalmology Annual Meeting in Chicago.
    • 20 Sep 2016 Planned End Date changed from 1 Feb 2019 to 1 Mar 2019.
    • 20 Sep 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top